Adaptimmune Archives

In Depth 3 Sep 2024

Adaptimmune: The long road toward finally bringing the first TCR-T cell therapy to the market

Find out about Adaptimmune’s long – and somewhat bumpy – road toward bringing the first TCR-T therapy to the market.

September 3, 2024 - 7 minutesmins - By Willow Shah-Neville

Best in Biotech 10 May 2023

5 cell therapy companies you should know about

Cell therapy has come a long way in recent years, with many biotech companies now specializing in the development of cell therapies to treat various diseases. In this article we take a look at five of those companies. Cell therapy refers to the transplantation of human cells in order to replace or repair damaged ones […]

May 10, 2023 - 6 minutesmins - By Willow Shah-Neville

Best in Biotech 17 Sep 2020

The Top 10 Biotech Companies Brewing at Oxford

Here are the top biotech companies in Oxford, a city in the U.K. with an old scientific tradition and an enormous output of biotech applications. Oxford is well known for its university, one of the oldest in Europe and considered to be one of the best in the world. Recently, the University of Oxford has […]

September 17, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Jan 2020

Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas

The UK biotech Adaptimmune Therapeutics has inked a deal worth up to €806M with Japanese Astellas Pharma to complete phase I trials of candidate off-the-shelf T-cell therapies for cancer including CAR T-cell and TCR therapies. According to the deal, Adaptimmune will collaborate with Universal Cells, a subsidiary of Astellas. The partners will aim to identify […]

January 15, 2020 - 2 minutesmins - By Jonathan Smith

Best in Biotech 21 May 2019

The Top 20 Women in Leading Biotech Roles in Europe

The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are more and more women filling leading roles in companies across Europe. Here are 20 women making an impact in the European biotech industry. Diversity comes […]

May 21, 2019 - 12 minutesmins - By Jonathan Smith

Helen Tayton Martin Adaptimmune interview

Interview 11 Sep 2018

How To Break Into The Crowded Immuno-Oncology Space

The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in this crowded field, many companies struggle to make therapies that not only are effective and safe, but that can also be scaled-up, manufactured and commercialized. Helen Tayton-Martin, Chief Business Officer at the biotech company Adaptimmune, shares her advice on how […]

September 11, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Jan 2018

Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy

Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity. Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine […]

January 9, 2018 - 3 minutesmins - By Alex Dale

News and Trends 8 Sep 2017

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

GSK has backed Adaptimmune in the development of their adaptable NY-ESO SPEAR T cell cancer therapy, causing an 11% jump in their premarket value. Adaptimmune has received support from GlaxoSmithKline (GSK) for the development of their NY-ESO SPEAR T cell, which will hopefully treat a range of different cancers. The British pharma giant will pay milestones of up to £48M (€52M) […]

September 8, 2017 - 2 minutesmins - By Alex Dale

Interview 20 Apr 2017

Which EU Immuno-Oncology Company are you Cheering for?

Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one do you think is doing it best? The field of immuno-oncology is overcrowded, and there’s plenty of companies pushing to make their cutting-edge technology a […]

April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […]

February 13, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Cell Therapies: Is Commercialization holding back a Breakthrough?

How far away is biotech from a breakthrough with cell and gene therapy? While these therapies have the potential to be the most effective on the market, they are still a long way away from that point, according to a pair of expert panels at BIO Europe last week. Everyone in cell therapy knows the […]

November 16, 2016 - 4 minutesmins - By Evelyn Warner

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Adaptimmune

Adaptimmune: The long road toward finally bringing the first TCR-T cell therapy to the market

5 cell therapy companies you should know about

The Top 10 Biotech Companies Brewing at Oxford

Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas

The Top 20 Women in Leading Biotech Roles in Europe

How To Break Into The Crowded Immuno-Oncology Space

Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

Which EU Immuno-Oncology Company are you Cheering for?

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Cell Therapies: Is Commercialization holding back a Breakthrough?

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!